Loading...
Products:Signal Transduction >> Protein Phosphorylation >> Tyrosine Kinases >> Receptor Tyrosine Kinases
If your product does not perform as described on this datasheet, we will refund or replace your product...
Read our guarantee »Anti-IGF1 Receptor (phospho Y1162 + Y1163) antibody
See all IGF1 Receptor products (22) ...
Rabbit polyclonal to IGF1 Receptor (phospho Y1162 + Y1163)
Although exhibiting a preference for IR/IGF-1R, this antibody has been shown by both peptide competition and protein blotting to react with other dual phosphotyrosine motifs from proteins such as c-Met and Shc.
Reacts with
Human
Predicted to work with
Mouse, Rat
Synthetic phosphopeptide derived from the region of Insulin Receptor/IGF1R that contains tyrosines 1162 and 1163. The corresponding residues in the IGF1R are 1135 and 1136.
CHO-T cells transfected with a vector containing insulin receptor and stimulated with 100 nM insulin for 10 minutes at 37°C.
Liquid
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Preservative: 0.05% Sodium Azide
Constituents: 50% Glycerol, PBS, 1mg/ml BSA. pH 7.3
Concentration information loading...
Immunogen affinity purified
The antibody has been negatively preadsorbed using a non-phosphopeptide corresponding to the site of phosphorylation to remove antibody that is reactive with non-phosphorylated Insulin Receptor (IR). The final product is generated by affinity chromatography using an IR-derived peptide phosphorylated at tyrosines 1162 and 1163(tyrosines 1135 and 1136 for IGF1R).
Polyclonal
IgG
Developmental Biology >> Post embryonic development >> Aging
Cancer >> Growth factors >> Insulin and insulin-like
Neuroscience >> Neurology process >> Metabolism
Signal Transduction >> Growth Factors/Hormones >> Insulin / Insulin-like
Signal Transduction >> Protein Phosphorylation >> Tyrosine Kinases >> Receptor Tyrosine Kinases
Western blot - Anti-IGF1 Receptor (phospho Y1162 + Y1163) antibody (ab5680)
(enlarge)
Our Abpromise guarantee covers the use of ab5680 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
WB: 1/1000. Detects a band of approximately 120 kDa.
Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R.
When present in a hybrid receptor with INSR, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.
Found as a hybrid receptor with INSR in muscle, heart, kidney, adipose tissue, skeletal muscle, hepatoma, fibroblasts, spleen and placenta (at protein level). Expressed in a variety of tissues. Overexpressed in tumors, including melanomas, cancers of the colon, pancreas prostate and kidney.
DEFects in IGF1R are a cause of insulin-like growth factor 1 resistance (IGF1RES) [MIM:270450]. It is a disorder characterized by intrauterine growth retardation and poor postnatal growth accompanied with increased plasma IGF1.
Belongs to the protein kinase superfamily. Tyr protein kinase family. Insulin receptor subfamily.
Contains 3 fibronectin type-III domains.
Contains 1 protein kinase domain.
Autophosphorylated on tyrosine residues in response to ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Autophosphorylation occurs in a sequential manner; Tyr-1165 is predominantly phosphorylated first, followed by phosphorylation of Tyr-1161 and Tyr-1166. While every single phosphorylation increases kinase activity, all three tyrosine residues in the kinase activation loop (Tyr-1165, Tyr-1161 and Tyr-1166) have to be phosphorylated for optimal activity. Can be autophosphorylated at additional tyrosine residues (in vitro). Autophosphorylated is followed by phosphorylation of juxtamembrane tyrosines and C-terminal serines. Phosphorylation of Tyr-980 is required for IRS1- and SHC1-binding. Dephosphorylated by PTPN1.
Ubiquitinated leading to its degradation by the proteasome.
Membrane.
Target information above from: UniProt accessionP08069
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).
Western blot - Anti-IGF1 Receptor (phospho Y1162 + Y1163) antibody (ab5680)

Peptide Competition: Extracts prepared from CHO-T cells transfected with an insulin receptor containing vector and left unstimulated (1) or stimulated with insulin (2-5) were resolved by SDS-PAGE on a 10% polyacrylamide gel and transferred to PVDF. Membranes were blocked with a 5% BSA TBST buffer overnight at 4°C and incubated with the ab5680 antibody for two hours at room temperature in a 3% BSA-TBST buffer, following prior incubation with: no peptide (1, 5), the phosphopeptide immunogen (2), the non-phosphorylated peptide corresponding to the phosphopeptide (3), or, a generic phosphotyrosine containing peptide (4). After washing, membranes were incubated with goat F(ab’)2 anti-rabbit IgG alkaline phosphatase conjugate and bands were detected using the Tropix WesternStar method. The data show that only the phosphopeptide corresponding to IR/IGF1R [pYpY1162/1163] completely blocks the antibody signal, thereby demonstrating the specificity of the antibody. The data also show the activation of the insulin receptor upon stimulation with insulin.
ab5680 has not yet been referenced specifically in any publications.
Publishing research using ab5680? Please let us know so that we can cite the reference in this datasheet
Concentration of lot no. is
Concentration not available for this lot.
Find concentration of your lot:

Peptide Competition: Extracts prepared from CHO-T cells transfected with an insulin receptor containing vector and left unstimulated (1) or stimulated with insulin (2-5) were resolved by SDS-PAGE on a 10% polyacrylamide gel and transferred to PVDF. Membranes were blocked with a 5% BSA TBST buffer overnight at 4°C and incubated with the ab5680 antibody for two hours at room temperature in a 3% BSA-TBST buffer, following prior incubation with: no peptide (1, 5), the phosphopeptide immunogen (2), the non-phosphorylated peptide corresponding to the phosphopeptide (3), or, a generic phosphotyrosine containing peptide (4). After washing, membranes were incubated with goat F(ab’)2 anti-rabbit IgG alkaline phosphatase conjugate and bands were detected using the Tropix WesternStar method. The data show that only the phosphopeptide corresponding to IR/IGF1R [pYpY1162/1163] completely blocks the antibody signal, thereby demonstrating the specificity of the antibody. The data also show the activation of the insulin receptor upon stimulation with insulin.
Peptide Competition: Extracts prepared from CHO-T cells transfected with an insulin receptor containing vector and left unstimulated (1) or stimulated with insulin (2-5) were resolved by SDS-PAGE on a 10% polyacrylamide gel and transferred to PVDF. Membranes were blocked with a 5% BSA TBST buffer overnight at 4°C and incubated with the ab5680 antibody for two hours at room temperature in a 3% BSA-TBST buffer, following prior incubation with: no peptide (1, 5), the phosphopeptide immunogen (2), the non-phosphorylated peptide corresponding to the phosphopeptide (3), or, a generic phosphotyrosine containing peptide (4). After washing, membranes were incubated with goat F(ab’)2 anti-rabbit IgG alkaline phosphatase conjugate and bands were detected using the Tropix WesternStar method. The data show that only the phosphopeptide corresponding to IR/IGF1R [pYpY1162/1163] completely blocks the antibody signal, thereby demonstrating the specificity of the antibody. The data also show the activation of the insulin receptor upon stimulation with insulin.
0
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Call 01223 696 000 or contact us
